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A B S T R A C T
A 52-year old male with a history of insulin treated T2DM complicated by end stage renal disease (ESRD
requiring hemodialysis and prior gastric bypass surgery presented with severe recurrent hypoglycemia
with seizures. A 72 hour fast demonstrated hyperinsulinemic hypoglycemia. Abdominal CT scan and en-
doscopic ultrasound guided biopsy demonstrated a pancreatic neuroendocrine tumor (pNET). Symptoms
persisted despite pNET resection and on further testing he was found to have a highly speciﬁc insulin
antibody resulting in insulin autoimmune syndrome. He responded well to prednisone therapy with res-
olution of hypoglycemia and decline in the insulin autoantibody titers. This study concludes that
autoimmune forms of hypoglycemia are uncommon and interpretation of tests can be challenging. However,
insulin autoimmune syndrome (IAS) should be considered in a patient with both fasting and postpran-
dial hypoglycemia in setting of very high insulin levels with associated anti-insulin antibodies and elevated
insulin to C peptide molar ratio.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The differential diagnosis in the symptomatic hypoglycemic
patient includes drugs, hepatic, renal, or cardiac failure, sepsis and
rarer etiologies such as insulinoma or insulin like growth factor-II
secreting tumors [1,2]. A key aspect of evaluation is to demon-
strate if the hypoglycemia occurs in the fasting or fed state and if
low glucose is associated with inappropriate insulin levels. We de-
scribe a patient with three distinct possible etiologies for
hypoglycemia that emphasizes the importance of the 72 hour fast
even when other etiologies may initially appear more likely.
A 52-year old Hispanic male with T2DM for 15 years compli-
cated by retinopathy, neuropathy and end stage renal disease (ESRD)
reportedweaknessanddiaphoresiswithbloodglucose (BG) <50mg/dl
relieved with food. Six years prior, he underwent an unknown type
of gastric bypass for obesity, lost 20 pounds and discontinued insulin
and oral diabeticmedications. Despite eating frequent small meals,
his symptomsworsenedwith daily seizures and BG of 30–40mg/dL.
Initial workup at outside hospital demonstrated BG of 30mg/dl,
an insulin level of 393 μU/ml (Normal range (NR) 3–25 μU/ml) and
C-peptide of 14.2 ng/ml (NR 1.1–4.3 ng/dL), suggesting endogenous
hyperinsulinemia. Abdominal CT noted 1.4 × 1.4 cm cystic pancreatic
headand6mmpancreatic tail lesions.Diazoxide100mgandoctreotide
200mcg TID did not prevent hypoglycemia associated seizures.
Closer inspection of home BG monitoring logs indicated the
patient was having both fasting and postprandial hypoglycemia. He
was admitted for a 72 hour fast (Figure 1) to further evaluate
the mechanism of his hypoglycemia [3]. Within 48 hours BG was
≤45 mg/dL with concomitant insulin 111 μU/ml, proinsulin
28.7 pmol/L (NR < 28.9 pmol/L), C-peptide 1.2 ng/ml and beta
hydroxybutyrate 2.1 mmol/L (NR < 0.4 mmol/L), conﬁrming
hyperinsulinemic hypoglycemia. Sulfonylurea screen including
metaglinide ingestion was negative and hepatic, adrenal and thyroid
function were normal. Endoscopic ultrasound guided biopsy of a
7 × 4 mm pancreatic tail lesion conﬁrmed neuroendocrine tumor.
At this juncture, we considered several etiologies for his hypo-
glycemia. Firstly his postprandial symptoms implicated his gastric
bypass. Secondly, he had fasting hyperinsulinemic hypoglycemia in
association with a biopsy proven NET. He also had ESRD with im-
paired insulin metabolism and lastly he had an insulin antibody at
258 μ/L (NR < 5), raising the additional possibility of autoimmuneme-
diatedhypoglycemia.As the tissuediagnosisof provenneuroendocrine
tumor might impact the patient’s future renal transplant eligibility,
he underwent distal spleen sparing pancreatectomy. Unexpectedly,
histopathology demonstrated a low grade glucagonoma with Ki-
67 <1%. (Figure1B, C). In reconsideringhis gastric bypass as anetiology
of thehypoglycemiaheunderwent a 100 goral glucose tolerance test.
No hypoglycemia was noted up to 7 hours after glucose loading, es-
sentially excluding bypass associated postprandial hypoglycemia. In
addition, we had considered if uremia could have contributed to his
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abnormal antibody binding. The only report of uremia interference
is with the Phenytoin assays. The metabolite 5-(p-hydroxyphenyl)-
5-phenylhydantoin (p-HPPH)cancross reactwith someassays.Uremia
is not reported to interfere in insulin immunoassays.
During a second 72 hour fast, BG fell to 44 mg/dl with concom-
itant total insulin 49 μU/ml and proinsulin 12.1 nmol/ml respectively.
Given the presence of an insulin antibody, we also measured free
insulin levels and these were not elevated. To investigate the po-
tential contribution of the insulin antibody to the patient’s
hypoglycemia, insulin level was quantiﬁed before and after incu-
bation with a Scant-bodies Heterophile blocking tube and
demonstrated 100% recovery of measured insulin excluding a het-
erophil antibody (Figure 2A). Serial dilution of patient’s serum did
not demonstrate linearity of insulin measurement in the Roche assay
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Figure 1. (A) 72 hour fast: Patient demonstrates fasting hypoglycemia with blood glucose <45 mg/dL and concomitantly elevated C-peptide, proinsulin and insulin levels
conﬁrming hyperinsulinemic hypoglycemia. (B) Hematoxylin and eosin staining of resected pancreatic tumor with (C) immunopositivity for glucagon but negative for insulin100×
magniﬁcation.
Figure 2. (A) Insulin levels were measured in triplicate before and after 1 hr incubation in a heterophilic blocking tube (treatment or TX) (Scantibodies Laboratory, Inc.).
* p < 0.05. (B) Patient and control samples were diluted 1 to 4 fold. Total insulin was then assayed using the Roche Cobas 8000 (upright triangles) or Beckman DXI (inverted
triangles). Insulin concentrations were corrected for the dilution factor and expressed as a percentage of the undiluted sample. (C) Insulin and bovine serum albumin (BSA)
(0.1–10 mg) were dot-blotted on nitrocellulose membranes and incubated with control and patient’s serum. (D) Control and patient’s serum were incubated with insulin
(200 μU/ml) then added along with 2 deoxyglucose (concn) to starved 3T3 murine ﬁbroblasts. ** p < 0.007.
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whereas recovery in the Beckman assay was within 10% of the ex-
pected insulin level (Figure 2B) and the Beckman assay was used
exclusively in this patient’s assessment.
The interference of anti-insulin antibodies in automated immu-
noassays for insulin is well described and validated for each
manufacturer’s insulin assay. The manufacturer for our in-house
insulin assay is Roche and this assay is known to suffer from pos-
itive interference from anti-insulin antibodies [4,5]. Since the insulin
levels measured in house did not correlate with the clinical pre-
sentation for this patient, we entertained the presence of an anti-
insulin interference and used an automated immunoassay from a
different manufacturer. We conﬁrmed that the patient’s anti-
insulin antibody did not interfere with insulin levels using
polyethylene glycol precipitation done by Kelly Chun at Esoterix
Laboratory Services, Inc.
Aliquots of patient and control serumwere also immunoblotted
against human insulin (0.1–10mg) and bovine serum albumin (BSA)
dot-blotted on nitrocellulose membranes [5]. As expected, control
serum (top and bottom panels of Figure 2C) did not bind either
insulin or BSA, whereas the patient’s serum bound insulin but did
not bind BSA.
Additionally patient and control serum aliquots were incu-
bated with Humalog insulin 200 μU/mL for 30 minutes at room
temperature, and then added along with 2-deoxyglucose (2-DG,
Sigma) overnight to glucose deprived murine 3T3-L1 cells for 40
min [6,7]. 2-DG uptake increased 2.3 ± 0.4-fold (mean ± SEM) in the
insulin pre-incubated control serum-treated cells, whereas no in-
crease in 2-DG uptake was observed in the cells treated with pre-
incubated patient serum (p = 0.007) (Figure 2 D). These studies
indicated that the patient’s serum contained a speciﬁc insulin
antibody that rapidly and eﬃciently bound insulin.
We concluded that the patient’s insulin antibody was inducing
his hypoglycemia. Treatment with oral prednisone 30 mg/d, with
slow tapering over 2 months led to resolution of hypoglycemia and
rapid fall in insulin autoantibody titers.
Discussion
Evaluation of the hypoglycemic patient can be challenging. An
inpatient 72 hour fast is often necessary to conﬁrm true hypogly-
cemia (BG <50 mg/dL) and determine if the hypoglycemia is either
insulin- or non-insulin-mediated. The most common cause of
hyperinsulinemic hypoglycemia in adults is an insulinoma and almost
always induces fasting hypoglycemia [8,9]. Hypoglycemia due to en-
dogenous hyperinsulinism can also be caused by sulfonylurea
medication or more rarely an insulin autoimmune syndrome (IAS)
[8–11].
This patient had several possible etiologies for his hypoglyce-
mia. Firstly, he had ESRD which due to reduced renal insulinase-
mediated insulin clearance can cause hypoglycemia [1,2]. Secondly,
this patient had undergone prior gastric bypass and postprandial
hypoglycemia has been reported in 0.1% of post-RYBG patients in
US patients [12].
There are two types of autoimmune hypoglycemia. In insulin
autoimmune syndrome (IAS) antibodies are directed against en-
dogenous insulin whereas in type B insulin resistance, antibodies
are directed against the cell surface insulin receptor. They can both
cause fasting and/or postprandial hypoglycemia. They are associ-
ated with hematologic and rheumatologic diseases, or may be
induced by sulfhydryl medications [9–11]. Our patient’s sister had
rheumatoid arthritis and another sister systemic lupus erythematous
(SLE), but he did not have a known autoimmune disorder. He did
not have a known history of sulfhydrylmedication ingestion although
givenmultiple antibiotics over many years, it is possible he may had
some prior sulfhydryl exposure.
IAS is common in Japan where it is the third leading cause of
spontaneous hypoglycemia but is increasingly recognized in non-
Asian populations [9]. In IAS, unlike type B insulin resistance, insulin,
C peptide and proinsulin levels are typicallymuch higher with insulin
often >1000 μU/mL and insulin:C peptide ratios 10–100. In IAS, food
ingestion prompts pancreatic insulin release; the latter is bound by
the insulin antibody leading to hyperglycemia and driving further
insulin secretion. Later, in the postprandial state when glucose levels
fall, kinetics of the insulin and insulin antibody aﬃnity alter re-
leasing insulin to induce hypoglycemia [10,11].
Our patient’s insulin antibody had high aﬃnity to insulin. In-
terestingly during hypoglycemia, measured free serum insulin levels
were not elevated. This raises the possibility that the insulin that
remained bound to the insulin antibody mediated this patient’s hy-
poglycemia. We think this is unlikely as it would require the bulky
insulin/insulin antibody complex to engage the insulin receptor. We
postulate that the insulin was dissociating from the insulin anti-
body in the target tissues perhaps in response to altered pH or other
conditions.
In summary, this case highlights the importance of the 72 hour
fast in the stepwise assessment of the hypoglycemic patient and
illustrates an unusual but increasingly encountered example of
autoimmune hypoglycemia.
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